Dynamic Advisors Solutions LLC purchased a new position in shares of Zimmer Biomet Holdings Inc (NYSE:ZBH) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 4,511 shares of the medical equipment provider’s stock, valued at approximately $544,000.
Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Private Advisor Group LLC boosted its position in shares of Zimmer Biomet by 18.6% during the third quarter. Private Advisor Group LLC now owns 6,733 shares of the medical equipment provider’s stock worth $791,000 after purchasing an additional 1,057 shares in the last quarter. Ingalls & Snyder LLC boosted its position in shares of Zimmer Biomet by 2.6% during the third quarter. Ingalls & Snyder LLC now owns 19,675 shares of the medical equipment provider’s stock worth $2,304,000 after purchasing an additional 507 shares in the last quarter. Jana Partners LLC boosted its position in shares of Zimmer Biomet by 16.6% during the third quarter. Jana Partners LLC now owns 4,662,497 shares of the medical equipment provider’s stock worth $545,932,000 after purchasing an additional 662,497 shares in the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS boosted its position in shares of Zimmer Biomet by 10.0% during the third quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 16,444 shares of the medical equipment provider’s stock worth $1,925,000 after purchasing an additional 1,494 shares in the last quarter. Finally, WINTON GROUP Ltd bought a new position in shares of Zimmer Biomet during the third quarter worth $370,000. 88.18% of the stock is currently owned by institutional investors.
Shares of Zimmer Biomet Holdings Inc (NYSE:ZBH) opened at $120.48 on Tuesday. The company has a debt-to-equity ratio of 0.76, a current ratio of 1.52 and a quick ratio of 0.83. Zimmer Biomet Holdings Inc has a 52 week low of $108.03 and a 52 week high of $133.49. The stock has a market cap of $24,393.96, a price-to-earnings ratio of 15.00, a price-to-earnings-growth ratio of 2.12 and a beta of 1.08.
Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings results on Tuesday, January 30th. The medical equipment provider reported $2.10 earnings per share (EPS) for the quarter, meeting the consensus estimate of $2.10. Zimmer Biomet had a net margin of 23.51% and a return on equity of 15.45%. The firm had revenue of $2.07 billion for the quarter, compared to analyst estimates of $2.03 billion. During the same period in the previous year, the business earned $2.14 EPS. The company’s revenue was up 3.0% compared to the same quarter last year. equities research analysts anticipate that Zimmer Biomet Holdings Inc will post 7.82 earnings per share for the current fiscal year.
The firm also recently declared a quarterly dividend, which was paid on Monday, January 29th. Shareholders of record on Friday, December 29th were paid a $0.24 dividend. The ex-dividend date of this dividend was Thursday, December 28th. This represents a $0.96 annualized dividend and a yield of 0.80%. Zimmer Biomet’s payout ratio is currently 10.65%.
In other Zimmer Biomet news, VP Chad F. Phipps sold 20,826 shares of Zimmer Biomet stock in a transaction on Monday, February 12th. The shares were sold at an average price of $115.95, for a total value of $2,414,774.70. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 1.07% of the stock is currently owned by insiders.
A number of equities analysts have recently weighed in on the stock. Cantor Fitzgerald reissued a “buy” rating and set a $140.00 price target on shares of Zimmer Biomet in a research report on Monday, February 5th. BMO Capital Markets reissued a “buy” rating and set a $144.00 price target on shares of Zimmer Biomet in a research report on Tuesday, January 30th. Leerink Swann lifted their price target on shares of Zimmer Biomet from $142.00 to $146.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 31st. Stifel Nicolaus raised shares of Zimmer Biomet from a “hold” rating to a “buy” rating and lifted their price target for the stock from $120.00 to $168.00 in a research report on Wednesday, January 31st. Finally, Robert W. Baird reissued a “buy” rating on shares of Zimmer Biomet in a research report on Wednesday, January 31st. Two investment analysts have rated the stock with a sell rating, four have assigned a hold rating, seventeen have issued a buy rating and one has assigned a strong buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $141.67.
COPYRIGHT VIOLATION NOTICE: “Dynamic Advisors Solutions LLC Invests $544,000 in Zimmer Biomet Holdings Inc (ZBH) Stock” was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this story on another website, it was illegally copied and republished in violation of US & international copyright & trademark laws. The legal version of this story can be accessed at https://www.dispatchtribunal.com/2018/02/20/dynamic-advisors-solutions-llc-invests-544000-in-zimmer-biomet-holdings-inc-zbh-stock.html.
About Zimmer Biomet
Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.
Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.